RSV WEBINAR SERIES February 2021

POSTER GALLERY

Evolutionary analysis of Human Respiratory Syncytial Virus in Myanmar, 2015-2018

The Seasonality of Respiratory Syncytial Virus and Associated Hospitalizations in High-risk Population in Hong Kong

Antiviral and anti inflammatory activity of synthetic steroidal analogues against the infection caused by Human Respiratory Syncytial Virus

The antiviral activity of the milk protein lactoferrin against the human Respiratory Syncytial Virus

In vitro and in vivo studies with recombinant clinical isolate-based respiratory syncytial virus in primary respiratory epithelial cultures, 2D airway organoids and small animal models

Respiratory Syncytial Virus Infections Continue to be a Growing Problem in the Care of Immunocompromised Patients Receiving Transplants

The Real-World Effectiveness of Palivizumab Programs for High-Risk Infants: A Population-Based Study in Ontario, Canada, 1993-2017

Estimating the underlying burden of respiratory syncytial virus infection among children and adults in Ontario, Canada: a modelling study

Community-Based Antibiotic Dispensing Attributable to Common Childhood Respiratory Viruses: A Population-Based Study of Scottish Children

A parainfluenza virus vector expressing the respiratory syncytial virus (RSV) prefusion F protein is more effective than RSV for boosting a primary immunization with RSV.

Intranasal and Intrapulmonary vaccination with an M protein-deficient respiratory syncytial virus (RSV) vaccine provides protection to infant baboons against an RSV challenge

Decreased human respiratory syncytial virus activity during COVID-19 pandemic in Japan associated with non-pharmaceutical measurement compared to pre- pandemic period

A hRSV-neutralizing prefusion F-specific single domain antibody that binds to a membrane-proximal site on F

The codon deoptimized, intranasally delivered, live attenuated RSV vaccine MV-012-968 is well tolerated and increases RSV preF specific IgA levels in healthy adults

Epidemiological profile of hospitalizations of Severe Acute Respiratory Infections by Respiratory Syncytial Virus and associated factors to ICU hospitalization and death in a Brazilian capital

Transplacental transfer of RSV antibody in Australian Aboriginal infants

Molecular Dissection of Human Antibody Responses Following Prefusion-Stabilized RSV F Vaccination

Bronchiolitis hospitalizations in rural New England, 2010 to 2017

Prophylactic effect of human and bovine lactoferrin against the respiratory syncytial virus in the mouse model

A Pilot Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Explore the Antiviral Activity, Clinical Outcomes, Safety and Tolerability of Rilematovir at Two Dose Levels in Non-hospitalized Adults Infected With Respiratory Syncytial Virus (RSV)

Save

Top

Skip to content

ISIRV LTD - Registered Address: 54a Castle Road, Isleworth, Middlesex, England TW7 6QS | Registered Company Number: 6021083 (England & Wales) | Registered Charity Number: 1118829

isirv

Font Size

SCREEN

Profile

Direction

Menu Style